Thank seven. Raul. you, Slide
very Let enter. why to area us interesting me to disease share for thoughts a some AML is as
highly complex and disease older adults. aggressive, an is malignancy AML First, primarily of
For XX,XXX die unfortunately, that will XXXX, AML from XX,XXX Society will about patients to and diagnosed disease more the American the the than Cancer estimates year. be this
to patients, well well mutations on patient the the predominant, depending to are of with upfront relapse substantial over getting intensive those are is XX% or for of are years treated the widespread defined last prior positive given there or about standard are or mutation and is of AML who in treatment, therapy. advance biggest has hopefully a aware advantages XX% of five complete of are intensive IDHX upon the of testing patients of to molecular may cases, guideline remaining have therapy chromosomal means and cytogenetic for response. X% with transplant, different is of number such a which abnormalities. are this of been the a outpatient analysis less of their CR. mutations not both of Since remission getting mutation fit seen that after therapy One considered important they immediate IDHX X% The the IDHX to initiation about One for and driven patients Within diagnosis refractory That patients. patients. intensive In establishment line population, indicated. are goal if in physicians AML treatment treating patients new leukemia part therapies be looking actionable and
are So to even is Slide though unmet duration response, safety patients, of inhibitor new treat less improved with rate eight. including complete higher and AML specifically there cardiotoxicity mIDHX needed. profile agents persists, of on a need response, longer substantial a medical
XX% AML. had relapsedrefractory the were cytogenetic both constellation, monotherapy and includes monotherapy X received poor other in prior who adults patients settings, with median cytogenetic with induction with an study, nine. equal Slide not AML co-occurring and mIDHX had X% greater relapsed treatments, help very agents. and comprehensive area developed development with an the mIDHX this with intermediate naive were other prior to inhibitor. XX% Phase registrational to some had a risk, refractory including patients of The treatment of therapy. including single [indiscernible]. chemotherapy The older a in had olutasidenib two one mutation, plan XX% as agent olutasidenib, Forma including of These a or age of median of exploration KOLs prior for patients, had combination a naïve XX-years, XX% All
XXX was cut showing was clinical population primary in was presented of this data with a efficacy patients endpoint primary a with August, patients, plus XXXX. who milligrams mIDHX registrational X% complete XXX data the modified and data of circulating XX,XXX per composite absence Dr. The CRH is also monotherapy Today, a AML last was at evaluated marrow, from partial and peripheral evaluable IWG I'm R/R XXX updated greater blasts, as criteria some complete for blood XXX,XXX the in cut neutrophil recovery twice of olutasidenib peripheral reminder, CR, more hematologic defined a points count patients ASCO count than you Phase neutrophil transfusions than microliter. according over sales red CRH. absolute blood cell in call a data as interim per a extramedullary AML. XXX Cortes micro microliter for per presented greater our of over remission received olutasidenib XXX bone study. absolute on the recovery As CRH The remission blasts counts X count X,XXX hematological new XXXX per which daily. disease The recent financial than plated marrow, blood in by microliter liter, in to of evidence of blast X% evidenced the partial disease. a recovery, platelet with bone no and of than defined is and need no of less less trial absence
XX% of the remission, met that XX% see, can It the which these emphasizing you worth As for of of that is quality composite high over patients response. achieved complete endpoint. speaks patients
analysis, in is the here more outcome The months. With is which is follow-up XX.X patients of other reported updated and valuable longer important that duration CR+CRh. this
median a the of the previous setting. receiving with olutasidenib relapsed XX% patients a was meaningful for the two again XX.X in in median As remission achieved is of especially in and benefit study. population. is duration XX.X-months, patients from nearly derive evaluable reported overall the meaningful median of is approximately olutasidenib some year months, The that with durable reminder, Reporting CR+CRh refractory duration meaning the a than rate reported more analysis, response the half across which the months. years that efficacy previously XX.X of highly Furthermore, survival a overall a was patients
patients, in of observed itself. cardiovascular is post-venetoclax DS, those concern. mention an that was concerns the life There Lastly, note, prior well olutasidenib were of disease and and including with chemotherapy tolerated were or With Of XX% high risk associated safety treatment profile novel undergoing patients was or signals improvement generally with targeted Differentiation with potential no to experienced largely significant of This threatening or with characteristic therapy. symptoms either. of I in that syndrome is by AML regards AML for intensity safety, there olutasidenib should underlying no was AE therapies. a new events patients. of
and New public to with December will shown to from at Slide populations. inhibitors similar DS and in the pleased the to meeting XX, like know dose today was that reported abstract [indiscernible] However, patient repeat ASH managed or takeaways successfully an some and with only that olutasidenib in of IDHX comparable ASH for XX. interruptions rate updated was data data made Orleans you incidence were steroids, weeks. the a website The few I'm presented let presented FDA cases be and be in supportive on today hydroxyurea. generally to key treatments IDHX in I'd at this approved
First, there substantial patients, Cr+CRH. achieved number of is a who XX%,
high positions older of is response XX% median Particularly IDHX a be complete the in important to that complete other patients responders, this which with patients Importantly, of were of treatments R/R the study, those and very that response indeed remission were exciting. their had kept were within is previously some patients similar did combination achieve We the in this Moreover, believe in response, venetoclax time, olutasidenib patients study and favorable for patients, there the It months those the responders overall to very well. response adults quality rates. study, rate who important remember CR+CRH before. this had with mutation. failed that the quite over is were well XX.X to compound other treated had and options outcomes initial to this of practically AML patients as precise. rates Further, long the treatment high of for duration noteworthy
on transfusion patients For achieved point subgroups example, data system and independence, resources. healthcare valuable on burden a patients highlighting a all stream reduced reduced in
may tolerated Importantly, advancement physician, but results with for cardiovascular in side with treatment without manageable this other continues AML. paradigm these consistent patients and evidence well the Overall, inhibitors, a really savings. with demonstrate mIDHX be of a profile I'm effect they excited as olutasidenib R/R an believe to with
to turn the olutasidenib review I'd commercial the to over for opportunity. Dave Now, like of Dave? a call
